The effect of proinflammatory cytokines on IL-17RA expression in NSCLC

Medical Oncology

Volumn 31, Issue 9, 2014, Pages 1-9

  Huang, Qi ^a   Du, Jiao ^a,b   Fan, Jinshuo ^a   Lv, Zhilei ^a   Qian, Xin ^a,c   Zhang, Xiuxiu ^a   Han, Jieli ^a   Chen, Caiyun ^a,d   Wu, Feng ^a   Jin, Yang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b XIAMEN UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

^d Xi'an First Social Welfare Hospital   (China)

Author keywords

IL 17RA; IL 1 ; IL 6; IL 8; NSCLC; TNF

Indexed keywords

EID: 84905554983     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0144-z     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Rodriguez MA, Walters RS, Burke TW. 60 Years of survival outcomes at the University of Texas MD Anderson Cancer Center. Berlin: Springer; 2013.
3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer decade of progress. CHEST J. 2002;122:1037–57.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
5. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81.
6. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang J-J, Kamimura D. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8–14.
7. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373–80.
8. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8:605–15.
9. Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets. 2011;15:1127–37.
10. Moseley T, Haudenschild D, Rose L, Reddi A. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155–74.
11. Yao Z, Fanslow WC, Seldin MF, Rousseau A-M, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995;3:811–21.
12. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17:366–9.
13. Honorati MC, Neri S, Cattini L, Facchini A. IL-17 enhances the susceptibility of U-2OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 2003;133:344–9.
14. Honorati MC, Cattini L, Facchini A. Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol. 2007;133:1017–21.
15. Lindemann MJ, Hu Z, Benczik M, Liu KD, Gaffen SL. Differential regulation of the IL-17 receptor by γc cytokines inhibitory signaling by the phosphatidylinositol 3-kinase pathway. J Biol Chem. 2008;283:14100–8.
16. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol. 2002;127:539–46.
17. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP. Synergy of IL-21 and IL-15 in regulating CD8 + T cell expansion and function. J Exp Med. 2005;201:139–48.
18. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–32.
19. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41.
20. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71:1–8.
21. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, Schwarzenberger P, Shellito JE, Kolls JK. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25:335–40.
22. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23:1069–75.
23. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem. 2006;281:24138–48.
24. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19:281–6.
25. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–89.
26. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011;186:3462–71.
27. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–54.
28. He G, Zhang B, Zhang B, Qiao L, Tian Z, Zhai G, Xin X, Yang C, Liu P, Zhang Y, Xu L. Th17 cells and IL-17 are increased in patients with brain metastases from the primary lung cancer. Zhongguo Fei Ai Za Zhi. 2013;16:476–81.
29. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE. 2011;6:e24856.
30. Klimatsidas M, Anastasiadis K, Foroulis C, Tossios P, Bisiklis A, Papakonstantinou C, Rammos K. Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions. J Cardiothorac Surg. 2012;7:104.
31. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett. 2012;148:144–50.
32. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177–89.
33. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185:6348–54.
34. Zhang GQ, Han F, Fang XZ. Ma XM [Expression of CD4(+) and IL-17, Foxp3 in non-small cell lung cancer and their correlation with microvessel density]. Zhonghua Zhong Liu Za Zhi. 2012;34:596–9.
35. Kaabachi W, Amor AB, Kaabachi S, Rafrafi A, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine. 2014;66:23–9.
36. Sansone P, Bromberg J. Environment, inflammation, and cancer. Curr Opin Genet Dev. 2011;21:80–5.
37. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci. 2010;101:2384–90.
38. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–97.
39. Chen K-H, Weng M-S, Lin J-K. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol. 2007;73:215–27.
40. Chang K-T, Tsai C-M, Chiou Y-C, Chiu C-H, Jeng K-S, Huang C-YF. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2005;289:L446–53.
41. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–41.
42. Lee IT, Lin CC, Wu YC, Yang CM. TNF-α induces matrix metalloproteinase-9 expression in A549 cells: role of TNFR1/TRAF2/PKCα-dependent signaling pathways. J Cell Physiol. 2010;224:454–64.